Related references
Note: Only part of the references are listed.Quality of life in inflammatory bowel diseases: it is not all about the bowel
Ronald Keller et al.
INTESTINAL RESEARCH (2021)
Crohn's disease
Giulia Roda et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Ulcerative colitis
Taku Kobayashi et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study
Lisa J. T. Smits et al.
INFLAMMATORY BOWEL DISEASES (2019)
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
Byong Duk Ye et al.
LANCET (2019)
Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil
Rogerio S. Parra et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers
Antonio Tursi et al.
ANNALS OF GASTROENTEROLOGY (2019)
Biosimilars in ulcerative colitis: When and for who?
Akos Ilias et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2018)
Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review
Javier P. Gisbert et al.
GASTROENTEROLOGIA Y HEPATOLOGIA (2018)
Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study
Ben Kang et al.
INFLAMMATORY BOWEL DISEASES (2018)
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Lawrence Blonde et al.
ADVANCES IN THERAPY (2018)
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
Viktoria Bergqvist et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2017)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Biosimilars in IBD: from theory to practice
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
Federico Arguelles-Arias et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2017)
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort
Lorant Gonczi et al.
INFLAMMATORY BOWEL DISEASES (2017)
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar
Gionata Fiorino et al.
INFLAMMATORY BOWEL DISEASES (2017)
Novel therapeutic targets for inflammatory bowel disease
Marjorie Argollo et al.
JOURNAL OF AUTOIMMUNITY (2017)
P629 Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year
G.E. Rodríguez Glez et al.
Journal of Crohns & Colitis (2017)
P430 EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experience
S. Nugent et al.
Journal of Crohns & Colitis (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis
Magdalena Kaniewska et al.
GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY (2017)
Long-Term Clinical Outcomes After Switching from RemicadeA® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Lisa J. T. Smits et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
F. Argulles-Arias et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases
Y. Komaki et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
M. Kolar et al.
DIGESTIVE DISEASES (2017)
Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO
Vito Annese et al.
JOURNAL OF CROHNS & COLITIS (2016)
Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
J. Sieczkowska et al.
JOURNAL OF CROHNS & COLITIS (2016)
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis
Klaudia Farkas et al.
JOURNAL OF CROHNS & COLITIS (2016)
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis
Radan Keil et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
The Budget Impact of Biosimilar Infliximab (Remsima(A (R))) for the Treatment of Autoimmune Diseases in Five European Countries
Ashok Jha et al.
ADVANCES IN THERAPY (2015)
A Multicenter, Randomized, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of PP-501-B in Correction of Nasolabial Folds
Kui Young Park et al.
DERMATOLOGIC SURGERY (2015)
Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Yoon Suk Jung et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Biologic agents for IBD: practical insights
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
Sang Hyoung Park et al.
Expert Review of Gastroenterology & Hepatology (2015)
Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study
Jørgen Jahnsen et al.
Expert Review of Gastroenterology & Hepatology (2015)
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study
Mirthe Emilie van der Valk et al.
GUT (2014)
The advent of biosimilar therapies in rheumatology-O Brave New World
Morton A. Scheinberg et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
Filip Baert et al.
GASTROENTEROLOGY (2010)
Clinical implications of mucosal healing for the management of IBD
Guillaume Pineton de Chambrun et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Mucosal Healing Predicts Long-term Outcome of Maintenance Therapy with Infliximab in Crohn's Disease
Fabian Schnitzler et al.
INFLAMMATORY BOWEL DISEASES (2009)
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Annabel Kuek et al.
POSTGRADUATE MEDICAL JOURNAL (2007)
Economics of the use of biologics in the treatment of inflammatory bowel disease
Russell D. Cohen et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2006)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2005)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
